scholarly journals Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

2018 ◽  
Vol Volume 13 ◽  
pp. 2557-2568 ◽  
Author(s):  
Roland Buhl ◽  
Carl-Peter Criée ◽  
Peter Kardos ◽  
Claus Vogelmeier ◽  
Konstantinos Kostikas ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real Life ◽  
Dual Bronchodilation

Dual bronchodilation vs triple therapy in the real-life DACCORD study

2018 ◽  
Author(s):  
Carl-Peter Criee ◽  
Peter Kardos ◽  
Heinrich Worth ◽  
Nadine Lossi ◽  
Konstantinos Kostikas ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Real Life ◽  
The Real ◽  
Dual Bronchodilation

scholarly journals Comparative effectiveness of triple therapy versus dual bronchodilation in COPD

2019 ◽  
Vol 5 (3) ◽  
pp. 00106-2019 ◽  
Author(s):  
Jaco Voorham ◽  
Massimo Corradi ◽  
Alberto Papi ◽  
Claus F. Vogelmeier ◽  
Dave Singh ◽  
...  
Keyword(s):  
Treatment Failure ◽  
Triple Therapy ◽  
Real Life ◽  
Blood Eosinophil ◽  
Exacerbation Rate ◽  
Historical Cohort ◽  
Respiratory Event ◽  
Dual Bronchodilation ◽  
Exacerbation Risk ◽  
Long Acting

This real-world study compared the effectiveness of triple therapy (TT; long-acting muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled corticosteroids (ICSs)) versus dual bronchodilation (DB; LAMAs/LABAs) among patients with frequently exacerbating COPD. A matched historical cohort study was conducted using United Kingdom primary care data. Patients with COPD aged ≥40 years with a history of smoking were included if they initiated TT or DB from no maintenance/LAMA therapy and had two or more exacerbations in the preceding year. The primary outcome was time to first COPD exacerbation. Secondary outcomes included time to treatment failure, first acute respiratory event, and first acute oral corticosteroid (OCS) course. Potential treatment effect modifiers were investigated. In 1647 matched patients, initiation of TT reduced exacerbation risk (adjusted hazard ratio (HR) 0.87, 95% CI 0.76–0.99), risk of acute respiratory event (HR 0.74, 95% CI 0.66–0.84) and treatment failure (HR 0.83, 95% CI 0.73–0.95) compared with DB. Risk reduction for acute respiratory events was greater for patients with higher rates of previous exacerbations. At baseline blood eosinophil counts (BECs) ≥ 0.35×109 cells·L−1, TT was associated with lower risk of OCS prescriptions than DB. This study provides real-life evidence of TT being more effective in reducing exacerbation risk than DB, which became more accentuated with increasing BEC and previous exacerbation rate.

Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based “Triple Therapy” Experience in Southern Italy

2016 ◽  
Vol 11 (4) ◽  
pp. 306-316 ◽  
Author(s):  
Filomena Morisco ◽  
Mario Masarone ◽  
Valerio Rosato ◽  
Silvia Camera ◽  
Rocco Granata ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Southern Italy ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

793 REAL-LIFE DATA OF TELAPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GT1 IN GERMANY – AN INTERIM ANALYSIS

2013 ◽  
Vol 58 ◽  
pp. S324 ◽  
Author(s):  
T. Berg ◽  
P. Buggisch ◽  
D. Hueppe ◽  
H. Wedemeyer ◽  
M. Schuier ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Triple Therapy ◽  
Chronic Hepatitis C ◽  
Interim Analysis ◽  
Real Life ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document